Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of ldl subfraction phenotype

被引:52
作者
Vinagre, Irene [1 ,2 ]
Luis Sanchez-Quesada, Jose [3 ]
Sanchez-Hernandez, Juan [4 ]
Santos, David [3 ,4 ]
Ordonez-Llanos, Jordi [3 ,5 ,6 ]
De Leiva, Alberto [1 ,7 ]
Perez, Antonio [1 ,4 ]
机构
[1] Hosp Santa Creu & Sant Pau, Endocrinol & Nutr Dept, Barcelona 08025, Spain
[2] Univ Autonoma Barcelona, E-08193 Barcelona, Spain
[3] IIB Sant Pau, Biomed Res Inst, Barcelona, Spain
[4] CIBER Diabet & Metab Dis CIBERDEM, Barcelona, Spain
[5] Hosp Santa Creu & Sant Pau, Dept Biochem, Barcelona 08025, Spain
[6] Univ Autonoma Barcelona, Dept Biochem & Mol Biol, E-08193 Barcelona, Spain
[7] CIBERBBN, Barcelona, Spain
来源
CARDIOVASCULAR DIABETOLOGY | 2014年 / 13卷
关键词
Inflammatory biomarkers; C-reactive protein; Adiponectin; Monocyte chemotactic protein-1; Transforming growth factor-beta(1); Tumor growth factor beta(1); Type; 2; diabetes; LDL phenotype; Atherogenic dyslipidemia; C-REACTIVE PROTEIN; INSULIN-RESISTANCE ATHEROSCLEROSIS; NECROSIS-FACTOR-ALPHA; ACUTE-PHASE PROTEINS; TNF-ALPHA; HYPERTENSIVE PATIENTS; SERUM CONCENTRATIONS; METABOLIC SYNDROME; MESANGIAL CELLS; ELEVATED LEVELS;
D O I
10.1186/1475-2840-13-34
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Type 2 diabetes mellitus (T2D) is associated with higher cardiovascular risk partly related to an increase in inflammatory parameters. The aim of this study was to determine the association of inflammatory biomarkers with low-density lipoprotein (LDL) subfraction phenotype and glycemic control in subjects with T2D and poor glycemic control. Methods: A cross-sectional study was performed comparing 122 subjects with T2D (59 +/- 11 years old, body mass index 30.2 +/- 5.6 kg/m2) with 54 control subjects. Patients with T2D were classified according to their LDL subfraction phenotype and inflammatory biomarkers (C-reactive protein, Interleukin-6, Interleukin-8, Transforming growth factor beta(1), Monocyte chemotactic protein 1, Leptin, Adiponectin) were evaluated according to the degree of glycemic control, LDL phenotype and other clinical characteristics. Forty-two subjects with T2D were studied before and after 3 months of improving glycemic control by different strategies. Results: Patients with T2D had higher C-reactive protein (CRP) and monocyte chemotactic protein-1 (MCP1) levels and lower adiponectin concentration, compared to controls. T2D subjects with body mass index >= 30 kg/m2 had higher CRP levels (5.2 +/- 4.8 mg/l vs 3.7 +/- 4.3 mg/l; p < 0.05). The presence of LDL phenotype B was related to higher levels of transforming growth factor-beta(1) (TGF-beta(1)) (53.92 +/- 52.82 ng/l vs 31.35 +/- 33.74 ng/l; p < 0.05) and lower levels of adiponectin (3663 +/- 3044 ng/l vs 2723 +/- 1776 ng/l; p < 0.05). The reduction of HbA1c from 9.5 +/- 1.8% at baseline to 7.4 +/- 0.8% was associated with a significant reduction of TGF-beta(1) (41.86 +/- 32.84 ng/l vs 26.64 +/- 26.91 ng/l; p = 0.02). Conclusions: Subjects with T2D, especially those with LDL phenotype B and obesity, have higher levels of inflammatory biomarkers. Improvement of glycemic control reduces TGF-beta(1) levels, which may contribute partly to its renoprotective role.
引用
收藏
页数:7
相关论文
共 42 条
[31]   Increased levels of C-reactive protein in noncontrolled type II diabetic subjects [J].
Rodríguez-Morán, M ;
Guerrero-Romero, F .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 1999, 13 (04) :211-215
[32]  
Sánchez-Quesada JL, 2002, J LIPID RES, V43, P699
[33]   Effect of Improving Glycemic Control in Patients With Type 2 Diabetes Mellitus on Low-Density Lipoprotein Size, Electronegative Low-Density Lipoprotein and Lipoprotein-Associated Phospholipase A2 Distribution [J].
Sanchez-Quesada, Jose L. ;
Vinagre, Irene ;
de Juan-Franco, Elena ;
Sanchez-Hernandez, Juan ;
Blanco-Vaca, Francisco ;
Ordonez-Llanos, Jordi ;
Perez, Antonio .
AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (01) :67-71
[34]   Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome [J].
Sciarretta, Sebastiano ;
Ferrucci, Andrea ;
Ciavarella, Giuseppino Massimo ;
De Paolis, Paola ;
Venturelli, Vanessa ;
Tocci, Giuliano ;
De Biase, Luciano ;
Rubattu, Speranza ;
Volpe, Massimo .
AMERICAN JOURNAL OF HYPERTENSION, 2007, 20 (07) :784-791
[35]   Monocyte chemotactic proten-1 and its vole in insulin resistance [J].
Sell, Henrike ;
Eckel, Juergen .
CURRENT OPINION IN LIPIDOLOGY, 2007, 18 (03) :258-262
[36]   Significance of platelet-activating factor acetylhydrolase in patients with non-insulin-dependent (type 2) diabetes mellitus [J].
Serban, M ;
Tanaseanu, C ;
Kosaka, T ;
Vidulescu, C ;
Stoian, I ;
Marta, DS ;
Tanaseanu, S ;
Moldoveanu, E .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2002, 6 (04) :643-647
[37]   Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report [J].
Suzuki, Hirofumi ;
Sakamoto, Masaya ;
Hayashi, Takeshi ;
Iuchi, Hiroyuki ;
Ohashi, Kennosuke ;
Isaka, Tsuyoshi ;
Sakamoto, Noriko ;
Kayama, Yosuke ;
Tojo, Katsuyoshi ;
Yoshimura, Michihiro ;
Utsunomiya, Kazunori .
CARDIOVASCULAR DIABETOLOGY, 2013, 12 :71
[38]   Initiation of insulin therapy reduces serum concentrations of high-sensitivity C-reactive protein in patients with type 2 diabetes [J].
Takebayashi, K ;
Aso, Y ;
Inukai, T .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2004, 53 (06) :693-699
[39]   Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus [J].
Tan, KCB ;
Chow, WS ;
Tam, SCF ;
Ai, VHG ;
Lam, CHL ;
Lam, KSL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (02) :563-568
[40]   Inflammatory Markers and Risk of Type 2 Diabetes A systematic review and meta-analysis [J].
Wang, Xia ;
Bao, Wei ;
Liu, Jun ;
OuYang, Ying-Ying ;
Wang, Di ;
Rong, Shuang ;
Xiao, Xiao ;
Shan, Zhi-Lei ;
Zhang, Yan ;
Yao, Ping ;
Liu, Lie-Gang .
DIABETES CARE, 2013, 36 (01) :166-175